Navigation Links
Cytel Announces Compass® - The Only Professional Adaptive Trial Software Package for Bayesian or Frequentist Dose-Finding Studies

CAMBRIDGE, Mass., Aug. 4 /PRNewswire/ -- Cytel Inc., premier provider of adaptive clinical trial design services and software, recently unveiled Compass®: the very first industrial strength software package for adaptive dose-finding studies based on frequentist or Bayesian methods.

The FDA's recently issued adaptive trial guidelines draft encourages adaptive design use, especially in attempts to identify the optimal dose level. 

Cytel has been at the forefront of applying adaptive trials in clinical practice for several years. Compass® has been developed from this experience and knowledge gained by East®, the extensively used adaptive and group sequential software for registration studies. Compass® now extends Cytel's adaptive design software line to include phase 2 dose-finding clinical trials.

Designers of dose ranging studies are challenged to find the correct dose(s) to carry into confirmatory development. The PhRMA Adaptive Dose Response Group has shown that adaptive methods often substantially improve on traditional designs at this crucial best dose determination stage.

Wider use of adaptive trials at this stage was previously inhibited by the lack of validated commercial software. Sponsor statisticians and their regulatory counterparts could only attempt to write their own statistical design code.

The advent of Compass® provides study planners with a workflow for modern dose identification study construction using accepted adaptive methods.  The built-in high-speed simulation engine quantifies design option decision-making, while visualizations of the trial characteristics improve understanding amongst both development teams and regulators, too.

A demonstration is replay-able at:

Of the release milestone, Compass® Product Manager, Yannis Jemiai, Ph.D., said: "We're very proud of our collective work to place modern, industrial strength adaptive design tools in the hands of the drug developers engaged in dose-finding clinical research. Compass® users will more easily choose the best options and conduct successful adaptive trials. Our trial simulations implementation is based on techniques proven to help sponsors to make knowledgeable decisions time and time again."  

About Cytel Inc.

47 of the top 50 biopharmaceutical firms use Cytel software to design, simulate and analyze their clinical studies. Cytel serves trial sponsors with innovative tools, training and consultation to increase clinical development efficiencies and success rates.

SOURCE Cytel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Judith Quinlan Joins Cytel as Vice President, Adaptive Trials
2. Cytels Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting
3. Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health (CDRH)
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
(Date:6/26/2016)... June 26, 2016 One of Australia,s ... the formation of a new biotechnology company, Noxopharm Limited [ABN 50 ... an IPO and to list on the ASX. Noxopharm ... ready to enter a Phase 1 clinical study later this year. ... address one of the biggest problems facing cancer patients - the ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... The ... OSHA Training Institute Education Center headquartered in Northern California, has issued an important ... heat at their worksites. Employers with workers exposed to high temperatures should ...
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... today its affiliation with Tennessee Counseling Association. This new relationship allows ... the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/27/2016)... Brooklyn, NY (PRWEB) , ... June 27, 2016 ... ... is using cutting edge technology to revolutionize the emergency ambulance transport experience for ... Many are aware of how Uber has disrupted the taxi industry through the ...
Breaking Medicine News(10 mins):